Weekly roundup
Hormonal health news Updated · 66d ago
FDA approvals, clinical trials, guideline updates, and pricing changes affecting women's hormonal health. Refreshed weekly. Subscribe for alerts if you want it pushed.
FDA FDA expands fezolinetant (Veozah) labeling to include moderate hot flashes
Astellas' Veozah, the first NK3 receptor antagonist for menopause vasomotor symptoms, now FDA-approved for moderate-intensity hot flashes (previously severe-only).
Expanded labeling means insurers may broaden coverage criteria. Manufacturer claims 60-65% reduction in moderate VMS frequency over 12 weeks.
Pricing Compounded GLP-1 median price drops 18% Q1 2026
Our monthly pricing index shows median compounded semaglutide moved from $249 to $204/month between Jan and April 2026. 503A pharmacy capacity expansion cited as driver.
Brands at the high end (Lifeforce, Henry Meds) held prices steady while value-tier brands (Hims, Mochi) cut deeply. Spread between p10 and p90 widened.
Guideline NAMS releases 2026 hormone therapy position statement
The North American Menopause Society updated its position on HRT, expanding eligibility window and emphasizing transdermal estrogen for cardiovascular safety.
"Window of opportunity" eligibility extended to 65 in healthy women. Transdermal estrogen now formally preferred over oral for most candidates.
Guideline Updated PCOS insulin resistance screening criteria
AACE/ACE 2026 update narrows insulin resistance screening to Rotterdam phenotype A only (hyperandrogenism + anovulation + cystic ovaries). Reduces over-screening.
Clinical trial Phase 3 trial: tirzepatide effect on postmenopausal bone density
SURPASS-Bone trial reports tirzepatide had neutral effect on bone density over 24 months in 1,247 postmenopausal women — contradicting earlier concerns from semaglutide observational data.
Industry Midi Health raises $80M Series C
Midi raises $80M led by Google Ventures, plans 50-state expansion and dedicated PCOS clinic integration.
Get this in your inbox
We send the weekly digest every Tuesday morning. 2-3 minute read, all linked on primary sources. Subscribe →